CYC-116

CYC-116 Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  CYC116 is a potent inhibitor of Aurora A/B and VEGFR with Ki of 8.0 nM/9.2 nM and 44 nM, respectively.

• Biologische Aktivität

  ki: 8.0 and 9.2 nm for aurora a and b, respectivelythe aurora kinases are a family of serine-threonine kinases that interact with components of the mitotic apparatus and that regulate aspects of centrosome maturation, bipolar spindle assembly, chromosome segregation, and cytokinesis. cyc116 has been discoverd as a novel n-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitor.

• in vitro

  the anticancer effects of cyc116 were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora a and b kinases. moreover, cyc116 was also assessed against other kinases [1].

• in vivo

  preliminary in vivo assessment showed that cyc116 was orally bioavailable and possessed anticancer activity. the mean relative tumor volumes of mice receiving cyc116 at both dose levels were less than those of vehicle-treated mice for the duration of the study period [1].

• target

  Aurora A

• IC 50

  44 and 19 nm respectively for aurora a and b in cancer cells

• Einzelnachweise

  [1] wang s, midgley ca, scaërou f, grabarek jb, griffiths g, jackson w, kontopidis g, mcclue sj, mcinnes c, meades c, mezna m, plater a, stuart i, thomas mp, wood g, clarke rg, blake dg, zheleva di, lane dp, jackson rc, glover dm, fischer pm. discovery of n-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. j med chem. 2010;53(11):4367-78.

CYC-116 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(125)Suppliers